COMMUNIQUÉS West-GlobeNewswire

ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London
06/11/2026
SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]
Azalea Therapeutics Presents New Preclinical Data at SITC 2026 Highlighting Durable Anti-Tumor Activity and Modular Capabilities of its In Vivo CAR T Cell Platform
06/11/2026
In vivo-engineered TRAC-CAR T cells demonstrate complete leukemia tumor clearance in mice, including following tumor rechallenge without additional dosing Modular platform enables dual-antigen targeting to limit tumor [...]
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
06/11/2026
- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8- [...]
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
06/11/2026
Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for [...]
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
06/11/2026
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent [...]
SOTIO Presents Initial Data from VICTORIA-01 Phase 1 Clinical Study of Immunocytokine SOT201 at SITC Annual Meeting
06/11/2026
SOT201, a novel cis-acting immunocytokine, combines IL-15 superagonist and anti-PD-1 activity in order to stimulate tumor specific T cells Data show early evidence of durable antitumor activity with SOT201, including [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2026
KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for [...]
Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
06/11/2026
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and [...]
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
06/11/2026
Bria-OTS+™ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor models BriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition [...]
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
06/11/2026
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma Findings provide an immunological mechanism for [...]
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
06/11/2026
Colorectal cance r: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale [...]
TOMI Environmental Solutions, Inc. Reschedules Third Quarter 2026 Earnings Call to Thursday, November 12
06/11/2026
FREDERICK, Md., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced it will reschedule its conference call [...]
Le KFSH de Riyad obtient la distinction « Global Elite Five-Star » de Davos Healthcare et figure parmi les 5 % des hôpitaux les mieux évalués au monde
06/11/2026
RIYAD, Arabie saoudite, 06 nov. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) de Riyad s’est vu décerner la médaille « Global Elite Five-Star » par Davos Healthcare, la plus [...]
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
06/11/2026
Detection of neoantigen-specific T cells directly ex vivo indicates strong EVX-01-induced immune responses Data further underlines the strong predictive performance of Evaxion’s AI-Immunology™ platform The new biomarker [...]
Major shareholder announcement - BlackRock, Inc.
06/11/2026
ANNOUNCEMENT NO. 326 6 November 2026 Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 2 November 2026, BlackRock, Inc. reduced [...]
Groundbreaking therapy for advanced heart failure: Repairon’s Scientific Co-Founder, Prof. Wolfram-Hubertus Zimmermann, Receives the 2026 “Galenus-von-Pergamon” Award for Outstanding Basic Pharmacological Research
06/11/2026
GÖTTINGEN, Germany and PROVIDENCE, R.I., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Professor Zimmermann and his research team are recognized for the development of iPSC-derived engineered heart muscle, Repairon’s BioVAT lead [...]
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
06/11/2026
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release [...]
Eccogene to Present Preclinical Data of Small Molecule Amylin and Calcitonin Receptor Agonist ECC1542 at ObesityWeek® 2026
06/11/2026
Poster presentation will highlight the preclinical profile of ECC1542 and its potential for treating obesity and associated comorbidities BOSTON and SHANGHAI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Eccogene, a global [...]
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
06/11/2026
WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]

Pages